Skip to main content

Drug Interactions between dengue vaccine and emapalumab

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

dengue vaccine emapalumab

Applies to: dengue vaccine and emapalumab

GENERALLY AVOID: The administration of live or live attenuated vaccines during emapalumab therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Emapalumab is a monoclonal antibody that binds to and neutralizes interferon gamma, which may increase susceptibility to certain pathogens and increase the risk of fatal and serious infections. In clinical trials, serious infections such as sepsis, pneumonia, bacteremia, disseminated histoplasmosis, necrotizing fasciitis, viral infections, and perforated appendicitis were observed in 32% of patients receiving emapalumab. The reported infections were 41% viral, 35% bacterial, 9% fungal, while in 15% of cases the pathogen was not identified. The safety of immunization with live vaccines during or following emapalumab therapy has not been studied.

MANAGEMENT: The use of live or live attenuated vaccines should be avoided during and for at least 4 weeks after the last dose of emapalumab.

References (1)
  1. (2018) "Product Information. Gamifant (emapalumab)." Sobi Inc

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer